Twist Bioscience
455 Mission Bay Blvd South
San Francisco
California
94158
United States
296 articles about Twist Bioscience
-
Twist Bioscience and IMIDomics Collaborate to Discover Antibodies for Applications in Immune-Mediated Inflammatory Diseases
9/27/2023
Twist Bioscience Corporation and IMIDomics, Inc. today announced a multi-program collaboration whereby Twist will utilize its antigen development capabilities and Library of Libraries to conduct antibody discovery activities against targets identified by IMIDomics.
-
Twist Bioscience to Present at Upcoming Investor Conferences - September 5, 2023
9/5/2023
Twist Bioscience Corporation today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, will participate in fireside chats at the following upcoming investor conferences.
-
Twist Bioscience Enters into Agreement with Ono Pharmaceutical to Discover Novel Antibodies for Autoimmune Diseases
8/31/2023
Twist Bioscience Corporation, a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, announced a drug discovery agreement with Ono Pharmaceutical Co., Ltd. to discover and develop novel antibodies for the treatment of autoimmune diseases.
-
Twist Bioscience Releases 2023 ESG Report and Quantifies Carbon Footprint of Manufacturing a Single Gene
8/22/2023
Twist Bioscience Corporation today released its environmental, social and governance (ESG) report for 2023, highlighting Twist’s approach to sustainability, social responsibility and commitment to ethics.
-
Twist Bioscience to Present at the UBS MedTech, Tools and Genomics Summit 2023
8/7/2023
Twist Bioscience Corporation today announced that Patrick Finn, Ph.D., president and COO of Twist Bioscience, will participate in the Innovation Across Drug Discovery, Molecule Synthesis, & Precision Medicine panel at the UBS MedTech, Tools and Genomics Summit 2023 on Tuesday, August 15 at 2:00 p.m. Pacific Time.
-
Twist Bioscience Reports Fiscal Third Quarter 2023 Financial Results
8/4/2023
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today reported financial results and business highlights for the third quarter of fiscal 2023 ended June 30, 2023.
-
Twist Bioscience to Report Fiscal 2023 Third Quarter Financial Results on Friday, August 4, 2023
7/20/2023
Twist Bioscience Corporation today announced that it will issue its financial results for the fiscal 2023 third quarter ended June 30, 2023, before the opening of the market on Friday, August 4, 2023.
-
Twist Bioscience and Cancer Research Horizons Enter into Collaboration to Advance Cancer Research
7/18/2023
Twist Bioscience Corporation and Cancer Research Horizons today announced an agreement under which Cancer Research Horizons will license the entire Twist Biopharma Solutions Library of Libraries.
-
Twist Bioscience Publishes Preclinical Data in Diabetes Validating GLP-1R Antagonist Antibody as Potential Treatment for Congenital Hyperinsulinism
6/26/2023
Twist Bioscience Publishes Preclinical Data in Diabetes Validating GLP-1R Antagonist Antibody as Potential Treatment for Congenital Hyperinsulinism.
-
Twist Bioscience Appoints Chet Gandhi as Chief Information Officer
6/20/2023
Twist Bioscience Corporation today announced the appointment of Chet Gandhi as chief information officer.
-
Twist Bioscience and CeGaT Launch RNA Fusion Panel to Advance Oncology and Precision Medicine Research
5/31/2023
Twist Bioscience Corporation and CeGaT GmbH today announced the launch of the Twist Alliance CeGaT RNA Fusion Panel, which is designed to detect RNA fusions and conduct transcript variant analysis for oncology research.
-
Twist Bioscience to Present at Upcoming Investor Conferences - May 24, 2023
5/24/2023
Twist Bioscience Corporation today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, and Jim Thorburn, CFO of Twist Bioscience, will present at the following upcoming investor conferences.
-
Twist Bioscience Appoints Robert Werner as Chief Accounting Officer
5/23/2023
Twist Bioscience Corporation today announced the appointment of Robert Werner as chief accounting officer.
-
Twist Bioscience Launches Portfolio of RNA Sequencing Tools
5/22/2023
Twist Bioscience Corporation today announced the launch of a portfolio of RNA sequencing tools, which includes the Twist RNA Exome, Twist RNA Library Prep Kit and the Twist Ribosomal RNA (rRNA) & Hemoglobin (Globin) Depletion Kit, as well as custom target enrichment capabilities for RNA and whole transcriptome sequencing.
-
Twist Bioscience to Present at ITF World 2023
5/10/2023
Twist Bioscience Corporation today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, will present at Imec Technology Forum (ITF) World 2023 in Antwerp, Belgium on Wednesday, May 17th at 11:10 AM CEST.
-
Twist Bioscience Reports Fiscal Second Quarter 2023 Financial Results
5/5/2023
Twist Bioscience Corporation today reported financial results and business highlights for the second quarter of fiscal 2023 ended March 31, 2023.
-
Twist Bioscience and Aster Insights Partner on Launch of Next Generation Oncology Panel for Cancer Research
4/27/2023
Twist Bioscience Corporation and Aster Insights today announced the availability of the AsterExome panel, which can simultaneously enable whole exome sequencing (WES) with additional coverage for target regions known to contain 620 genes associated with cancer.
-
Twist Bioscience Enters into Third Collaboration with Astellas to Support Antibody Discovery for Immunotherapies
4/20/2023
Twist Bioscience Corporation today announced a collaboration with Astellas Pharma Inc.
-
Twist Bioscience to Report Fiscal 2023 Second Quarter Financial Results on Friday, May 5, 2023
4/13/2023
Twist Bioscience Corporation today announced that it will issue its financial results for the fiscal 2023 second quarter ended March 31, 2023, before the opening of the market on Friday, May 5, 2023.
-
Twist Bioscience Announces Robust Antibody Discovery Services Integrating In Vivo, In Vitro and In Silico Approaches
3/9/2023
Twist Bioscience Announces Robust Antibody Discovery Services Integrating In Vivo, In Vitro and In Silico Approaches.